தய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from தய்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In தய்ச்சி Today - Breaking & Trending Today
Oral presentation highlights data from phase 1 study of valemetostat showing promising clinical activity in patients with relapsed/refractory PTCL and ATL Pivotal phase 2 study VALENTINE-PTCL01 ....
Oral presentation highlighting extended follow-up data from phase 1 study in patients with locally advanced or metastatic TKI-resistant, EGFR-mutated NSCLC shows promising clinical activity Data ....
Daiichi Sankyo FY20 Profit Down; Sees Higher Operating Profit, Revenues In FY21 TOKYO (dpa-AFX) - Daiichi Sankyo Co. Ltd. (DSKYF.PK), a Japanese pharmaceutical company, reported Tuesday that its fiscal 2020 profit attributable to owners of the company declined 41.2 percent to 75.96 billion yen from the prior year s 129.07 billion yen. Earnings per share fell to 39.11 yen from 66.27 yen last year. Operating profit declined 54 percent year on year to 63.80 billion yen. Revenue for the period dropped 2 percent to 962.52 billion yen from last year s 981.79 billion yen. Looking ahead for fiscal 2021, the company expects attributable profit of 50 billion yen or 26.09 yen, down 34.2 percent year-over-year. Operating profit is expected to be 70 billion yen, up 9.7 percent, while core operating profit would be down 11.2 percent to 70 billion yen. ....
Daiichi Sankyo Company, Limited: DESTINY-CRC02 Phase 2 Trial of ENHERTU Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer Interstitial Lung Disease Pneumonitis Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in =28 days from date of onset, maintain dose. If resolved in >28 days from date of onset, reduce dose one level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., =0.5 mg/kg/day prednisolone or equivalent). For symptomatic ILD/ ....